Cleerly is creating a new standard of care for heart disease. Through its FDA-cleared, value-based diagnostic solutions driven by artificial and machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Rather than studying surrogates of the number one killer, heart disease, Cleerly is shifting the care paradigm from treating late-stage symptoms to proactively identifying early stages of disease when its progression can be more easily prevented.
One of the greatest value-adds from working with Tripp and the LRV team — beyond their unparalleled expertise and understanding of the intricacies of how the US healthcare system actually works — is their willingness and enthusiasm to serve as both thought and action partners. They have offered us unique and strategic insights to help scale our efforts across several distinct healthcare delivery models, as well as demonstrated both enthusiasm and willingness to “roll up their sleeves” to partner with us in establishing a new standard of care for the prevention of heart disease.
- Jim Min, Founder and CEO